Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase 1 2

Status

Completed 7Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 7

Study Type

Interventional 7

Sponsor

Cancer Type

Other hematologic neoplasm 4Tumor-Agnostic 1Other solid neoplasm 1Myeloid 1

Conditions

Hematologic Neoplasms 4Solid Tumor 1Primary Myelofibrosis 1Neoplasms 1Myeloproliferative Disorders 1

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Completed × INDUSTRY × fedratinib × Clear all
NCT03952039 2025-08-28

FREEDOM2

Celgene

Phase 3 Completed
202 enrolled 23 charts
Myeloid

Myeloproliferative Disorders, Primary Myelofibrosis

NCT01420770 2025-03-05

Phase 2 Study of SAR302503 in Patients With Myelofibrosis

Bristol-Myers Squibb

Phase 2 Completed
30 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

NCT01420783 2025-03-05

Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia

Bristol-Myers Squibb

Phase 2 Completed
81 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

NCT01437787 2025-03-05

JAKARTA

Bristol-Myers Squibb

Phase 3 Completed
289 enrolled 1 FDA
Other hematologic neoplasm

Hematologic Neoplasms

NCT01523171 2025-03-05

JAKARTA2

Bristol-Myers Squibb

Phase 2 Completed
97 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

NCT01585623 2025-03-05

Drug Interaction Study of SAR302503 in Patients With Solid Tumor

Bristol-Myers Squibb

Phase 1 Completed
16 enrolled
Other solid neoplasm

Solid Tumor

NCT01836705 2025-03-05

Effect of SAR302503 on ECG Activity in Patients With Solid Tumors

Bristol-Myers Squibb

Phase 1 Completed
60 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡